Regeneron COVID-19 Therapeutic, Novavax Vaccine Get BARDA Funding To Boost Manufacturing

US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.

Manufacturing and Covid-19 virus, symbolized by viruses destroying word Manufacturing to picture that coronavirus outbreak destroys Manufacturing, blurred background, 3d illustration
Government Funds Manufacturing Of COVID-19 Therapeutic And Vaccine • Source: Shutterstock

The US government's Operation Warp Speed is providing $450m to Regeneron Pharmaceuticals, Inc. to support large-scale manufacturing of its investigational COVID-19 therapeutic and $1.6bn to Novavax, Inc. for late-stage clinical development and large-scale manufacturing of its COVID-19 vaccine candidate.

The awards are a boon for the companies, as ramping up production for worldwide supply of COVID-19 products is a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance